Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)‘s stock had its “hold” rating reissued by research analysts at FBR & Co in a research note issued to investors on Monday.

ALXN has been the subject of several other reports. Vetr cut Alexion Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $107.00 target price for the company. in a research note on Tuesday, October 18th. Jefferies Group dropped their price target on Alexion Pharmaceuticals from $140.00 to $120.00 and set a “hold” rating for the company in a research note on Friday, September 23rd. Leerink Swann increased their price target on Alexion Pharmaceuticals from $210.00 to $211.00 and gave the company an “outperform” rating in a research note on Monday, September 26th. Zacks Investment Research upgraded Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, September 27th. Finally, Citigroup Inc. increased their price target on Alexion Pharmaceuticals from $154.00 to $155.00 and gave the company a “buy” rating in a research note on Tuesday, September 20th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. Alexion Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $173.36.

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 118.89 on Monday. Alexion Pharmaceuticals has a one year low of $110.56 and a one year high of $193.45. The stock’s 50 day moving average price is $123.55 and its 200-day moving average price is $130.23. The firm has a market cap of $26.65 billion, a price-to-earnings ratio of 72.49 and a beta of 1.45.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.04 by $0.19. Alexion Pharmaceuticals had a return on equity of 10.58% and a net margin of 12.46%. The firm earned $799 million during the quarter, compared to analysts’ expectations of $787.07 million. During the same period in the prior year, the company earned $1.16 earnings per share. The company’s quarterly revenue was up 19.9% on a year-over-year basis. Analysts forecast that Alexion Pharmaceuticals will post $4.64 earnings per share for the current year.

In other news, SVP Edward Miller sold 367 shares of the business’s stock in a transaction that occurred on Friday, September 9th. The stock was sold at an average price of $128.32, for a total value of $47,093.44. Following the transaction, the senior vice president now owns 16,519 shares in the company, valued at approximately $2,119,718.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Leonard Bell sold 37,317 shares of the business’s stock in a transaction that occurred on Friday, November 4th. The stock was sold at an average price of $140.38, for a total value of $5,238,560.46. Following the completion of the transaction, the director now owns 440,936 shares in the company, valued at approximately $61,898,595.68. The disclosure for this sale can be found here. Company insiders own 4.41% of the company’s stock.

Several institutional investors have recently made changes to their positions in ALXN. Envestnet Asset Management Inc. increased its position in shares of Alexion Pharmaceuticals by 19.8% in the first quarter. Envestnet Asset Management Inc. now owns 28,327 shares of the biopharmaceutical company’s stock worth $3,944,000 after buying an additional 4,688 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in shares of Alexion Pharmaceuticals during the first quarter worth $418,000. Arizona State Retirement System increased its position in shares of Alexion Pharmaceuticals by 0.8% in the first quarter. Arizona State Retirement System now owns 61,100 shares of the biopharmaceutical company’s stock worth $8,506,000 after buying an additional 500 shares during the last quarter. First Republic Investment Management Inc. increased its position in shares of Alexion Pharmaceuticals by 3.0% in the first quarter. First Republic Investment Management Inc. now owns 8,039 shares of the biopharmaceutical company’s stock worth $1,120,000 after buying an additional 232 shares during the last quarter. Finally, Raymond James Trust N.A. increased its position in shares of Alexion Pharmaceuticals by 17.7% in the second quarter. Raymond James Trust N.A. now owns 4,268 shares of the biopharmaceutical company’s stock worth $499,000 after buying an additional 643 shares during the last quarter. Hedge funds and other institutional investors own 97.33% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.